In my cart

You have no items in your shopping cart.

PD 0325901


Product overview

  • Name
    PD 0325901
  • Short description
    Potent MEK1 and MEK2 inhibitor. Enhances iPSCs generation.
  • Biological description

    Potent, non-ATP competitive MEK1 (MKK1) and MEK2 (MKK2) inhibitor (Ki values are 0.79 and 1.1 nM at MEK1 and MEK2 respectively).

    Cell permeable.

    Induces G1-phase cell cycle arrest and apoptosis and inhibits melanoma cell line growth in vitro and in vivo.

    Increases reprogramming efficiency of human primary fibroblasts into iPSCs when combined with SB 431542 and also prevents cell differentiation and sustains self-renewal of ESCs when combined with CHIR 99021

  • Biological action
  • Purity
  • Citations


  • Chemical name
    N-[(2R)-2,3-Dihydroxypropoxy]-3,4-d ifluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide
  • Molecular Weight
  • Chemical structure
    PD 0325901 | PD325901  [391210-10-9]
  • Molecular Formula
  • CAS Number
  • PubChem identifier
  • InChi
  • InChiKey
  • MDL number

Storing and Using Your Product

  • Storage instructions
  • Solubility overview
    Soluble in DMSO (25mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for PD 0325901

  • A chemical platform for improved induction of human iPSCs.

    Lin et al (2009) Nat Methods 6(11) : 805-8
    PubMedID: 19838168
  • The ground state of embryonic stem cell self-renewal.

    Ying et al (2008) Nature 453(7194) : 519-23
    PubMedID: 18497825
  • The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

    Barrett et al (2008) Bioorg Med Chem Lett 18(24) : 6501-4.
    PubMedID: 18952427
  • Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

    Ciuffreda et al (2009) Neoplasia 11(8) : 720-31.
    PubMedID: 19649202
Support & Resources